Literature DB >> 16432188

A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy.

Kobra Haghighi1, Fotis Kolokathis, Anthony O Gramolini, Jason R Waggoner, Luke Pater, Roy A Lynch, Guo-Chang Fan, Dimitris Tsiapras, Rohan R Parekh, Gerald W Dorn, David H MacLennan, Dimitrios Th Kremastinos, Evangelia G Kranias.   

Abstract

The sarcoplasmic reticulum Ca(2+)-cycling proteins are key regulators of cardiac contractility, and alterations in sarcoplasmic reticulum Ca(2+)-cycling properties have been shown to be causal of familial cardiomyopathies. Through genetic screening of dilated cardiomyopathy patients, we identified a previously uncharacterized deletion of arginine 14 (PLN-R14Del) in the coding region of the phospholamban (PLN) gene in a large family with hereditary heart failure. No homozygous individuals were identified. By middle age, heterozygous individuals developed left ventricular dilation, contractile dysfunction, and episodic ventricular arrhythmias, with overt heart failure in some cases. Transgenic mice overexpressing the mutant PLN-R14Del recapitulated human cardiomyopathy exhibiting similar histopathologic abnormalities and premature death. Coexpression of the normal and mutant-PLN in HEK-293 cells resulted in sarcoplasmic reticulum Ca(2+)-ATPase superinhibition. The dominant effect of the PLN-R14Del mutation could not be fully removed, even upon phosphorylation by protein kinase A. Thus, by chronic suppression of sarcoplasmic reticulum Ca(2+)-ATPase activity, the nonreversible superinhibitory function of mutant PLN-R14Del may lead to inherited dilated cardiomyopathy and premature death in both humans and mice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432188      PMCID: PMC1360586          DOI: 10.1073/pnas.0510519103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Transmembrane helix M6 in sarco(endo)plasmic reticulum Ca(2+)-ATPase forms a functional interaction site with phospholamban. Evidence for physical interactions at other sites.

Authors:  M Asahi; Y Kimura; K Kurzydlowski; M Tada; D H MacLennan
Journal:  J Biol Chem       Date:  1999-11-12       Impact factor: 5.157

Review 2.  Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.

Authors:  Silvia G Priori; Carlo Napolitano
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 3.  Alterations of calcium-regulatory proteins in heart failure.

Authors:  G Hasenfuss
Journal:  Cardiovasc Res       Date:  1998-02       Impact factor: 10.787

4.  Phospholamban inhibitory function is activated by depolymerization.

Authors:  Y Kimura; K Kurzydlowski; M Tada; D H MacLennan
Journal:  J Biol Chem       Date:  1997-06-13       Impact factor: 5.157

5.  Cardiac-specific overexpression of a superinhibitory pentameric phospholamban mutant enhances inhibition of cardiac function in vivo.

Authors:  J Zhai; A G Schmidt; B D Hoit; Y Kimura; D H MacLennan; E G Kranias
Journal:  J Biol Chem       Date:  2000-04-07       Impact factor: 5.157

6.  The human phospholamban gene: structure and expression.

Authors:  C F McTiernan; C S Frye; B H Lemster; E A Kinder; M L Ogletree-Hughes; C S Moravec; A M Feldman
Journal:  J Mol Cell Cardiol       Date:  1999-03       Impact factor: 5.000

7.  Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure.

Authors:  Xander H T Wehrens; Stephan E Lehnart; Steven Reiken; Roel van der Nagel; Raymond Morales; Jie Sun; Zhenzhuang Cheng; Shi-Xiang Deng; Leon J de Windt; Donald W Landry; Andrew R Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-22       Impact factor: 11.205

8.  Maximal inhibition of SERCA2 Ca(2+) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban.

Authors:  A G Brittsan; A N Carr; A G Schmidt; E G Kranias
Journal:  J Biol Chem       Date:  2000-04-21       Impact factor: 5.157

9.  Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy.

Authors:  M Meyer; W Schillinger; B Pieske; C Holubarsch; C Heilmann; H Posival; G Kuwajima; K Mikoshiba; H Just; G Hasenfuss
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

10.  Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation.

Authors:  W Luo; I L Grupp; J Harrer; S Ponniah; G Grupp; J J Duffy; T Doetschman; E G Kranias
Journal:  Circ Res       Date:  1994-09       Impact factor: 17.367

View more
  143 in total

Review 1.  Evolving molecular diagnostics for familial cardiomyopathies: at the heart of it all.

Authors:  Thomas E Callis; Brian C Jensen; Karen E Weck; Monte S Willis
Journal:  Expert Rev Mol Diagn       Date:  2010-04       Impact factor: 5.225

Review 2.  Calcium cycling proteins and their association with heart failure.

Authors:  L Hadri; R J Hajjar
Journal:  Clin Pharmacol Ther       Date:  2011-08-10       Impact factor: 6.875

3.  Gene therapy for inherited arrhythmias.

Authors:  Vassilios J Bezzerides; Maksymilian Prondzynski; Lucie Carrier; William T Pu
Journal:  Cardiovasc Res       Date:  2020-07-15       Impact factor: 10.787

4.  Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein.

Authors:  Eric J Jaehnig; Analeah B Heidt; Stephanie B Greene; Ivo Cornelissen; Brian L Black
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

5.  Upregulation of SERCA2a following short-term ACE inhibition (by enalaprilat) alters contractile performance and arrhythmogenicity of healthy myocardium in rat.

Authors:  Marek Matus; Dana Kucerova; Peter Kruzliak; Adriana Adameova; Gabriel Doka; Katarina Turcekova; Jana Kmecova; Jan Kyselovic; Peter Krenek; Uwe Kirchhefer; Frank U Mueller; Peter Boknik; Jan Klimas
Journal:  Mol Cell Biochem       Date:  2015-02-08       Impact factor: 3.396

6.  Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy.

Authors:  Hu Wang; Zhaohui Li; Jizheng Wang; Kai Sun; Qiqiong Cui; Lei Song; Yubao Zou; Xiaojian Wang; Xuan Liu; Rutai Hui; Yuxin Fan
Journal:  Am J Hum Genet       Date:  2010-10-21       Impact factor: 11.025

7.  Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy.

Authors:  Lennart Suckau; Henry Fechner; Elie Chemaly; Stefanie Krohn; Lahouaria Hadri; Jens Kockskämper; Dirk Westermann; Egbert Bisping; Hung Ly; Xiaomin Wang; Yoshiaki Kawase; Jiqiu Chen; Lifan Liang; Isaac Sipo; Roland Vetter; Stefan Weger; Jens Kurreck; Volker Erdmann; Carsten Tschope; Burkert Pieske; Djamel Lebeche; Heinz-Peter Schultheiss; Roger J Hajjar; Wolfgang C Poller
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

8.  Functional and transcriptomic insights into pathogenesis of R9C phospholamban mutation using human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Delaine K Ceholski; Irene C Turnbull; Chi-Wing Kong; Simon Koplev; Joshua Mayourian; Przemek A Gorski; Francesca Stillitano; Angelos A Skodras; Mathieu Nonnenmacher; Ninette Cohen; Johan L M Björkegren; Daniel R Stroik; Razvan L Cornea; David D Thomas; Ronald A Li; Kevin D Costa; Roger J Hajjar
Journal:  J Mol Cell Cardiol       Date:  2018-05-09       Impact factor: 5.000

Review 9.  Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.

Authors:  Elham Kayvanpour; Farbod Sedaghat-Hamedani; Ali Amr; Alan Lai; Jan Haas; Daniel B Holzer; Karen S Frese; Andreas Keller; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2016-08-30       Impact factor: 5.460

Review 10.  Remodeling of cell-cell junctions in arrhythmogenic cardiomyopathy.

Authors:  Angeliki Asimaki; Jeffrey E Saffitz
Journal:  Cell Commun Adhes       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.